Table 3 Physician recommendations for statin treatment by intervention group compared to NCEP III guidelines and a tailored treatment approach
ATP III NCEP III statin treatment recommendation | Benefit based therapy statin treatment recommendation | Proportion of control group prescribing statin therapy | Proportion of experimental group prescribing statin therapy | Mean difference* [control -experimental groups [95% CI] | Pvalue | |
|---|---|---|---|---|---|---|
Case 1. 52 year-old woman: 10-year risk, 2%; LDL-C (175 mg/dL) | Optional | No statin | 0.76 | 0.67 | 0.09 [0.007, 0.167] | 0.03 |
Case 2. 70 year-old man male: 10-year risk, 22%; LDL-C (128 mg/dL) | Optional | High-potency statin | 0.41 | 0.73 | -0.32 [-0.397, -0.231] | <0.001 |
Case 3. 55 year-old woman: 10-year risk, 7%; LDL-C (135 mg/dL) | No | Moderate-potency statin | 0.74 | 0.65 | 0.09 [0.003, 0.166] | 0.04 |
Case 4. 52 year-old man: 10-year risk, 13%; LDL-C (90 mg/dL) | No | Moderate-potency statin | 0.20 | 0.26 | -0.06 [-0.136, 0.132] | 0.11 |
Case 5. 71 year-old man: 10-year risk, 21%; LDL-C (96 mg/dL) | No | High-potency statin | 0.12 | 0.27 | -0.16 [-0.225, -0.085] | <0.001 |